Key result
Rosuvastatin cuts LDL-C by up to ~65%, outperforming atorvastatin in Phase III trials.
Why the study?
Rosuvastatin's efficacy and tolerability compared to atorvastatin for treating dyslipidaemia required comprehensive evaluation.
Does rosuvastatin improve lipid profiles compared to atorvastatin in patients with dyslipidaemia?
Does rosuvastatin improve lipid profiles compared to atorvastatin in patients with dyslipidaemia?
Rosuvastatin is a highly efficacious statin that provides significant LDL-C reduction and HDL-C elevation, allowing most patients to reach ATP III goals with a 10 mg starting dose.
Answers are grounded in this paper and cite their sources.
May support rosuvastatin preference for LDL-C goals in dyslipidaemia; extends comparative lipid data but leaves outcome trials open.
Rosuvastatin is a synthetic enantiomer that is hepatoselective, relatively hydrophilic and has minimal metabolism via the cytochrome P450 3A4 system (similar to pravastatin). Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The majority of HMG-CoA reductase inhibitory activity in plasma is associated with the parent rosuvastatin compound. In a Phase II study, rosuvastatin across a dose range of 1- 80 mg lowered low-density lipoprotein cholesterol (LDL-C) by 34 - 65%. Phase III trials have demonstrated greater reductions in LDL-C for rosuvastatin compared to atorvastatin as well as greater increases in high-density lipoprotein cholesterol (HDL-C). The drug appears to be well tolerated at all doses up to 80 mg/day. A starting dose of 10 mg will reduce LDL-C by approximately 50%, which should adequately treat most patients to within the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) goals.
No takes yet. Share an insight, caveat, or question.
Michael H. Davidson (2002) conducted a review in dyslipidaemia. Rosuvastatin vs. atorvastatin was evaluated on low-density lipoprotein cholesterol (LDL-C) reduction. Rosuvastatin at doses of 1- lowered LDL-C by 34-65% and demonstrated greater reductions in LDL-C compared to atorvastatin in Phase III trials.
Synapse has enriched 10 related papers. Consider them for comparative context: